News

Global Leader in Regenerative Medicine: 30 Years Strong & Growing

Posted by curasan on 3/13/18 6:27 PM

30-Years-Strong-and-Growing_REV.jpg

Thirty years ago, curasan was born.

From that day forward they have become a pioneer and global technology leader in the growing field of regenerative medicine. They founded the best research teams and development engineers the industry has ever experienced.

As an industry leader, curasan is an innovative developer, manufacturer, and marketer of biomaterials for bone and tissue regeneration for the world-wide dental and orthopedic markets, with a focus on delivering these innovative biomaterials to its customers to help their patients and clinical outcomes.

They develop, manufacture, and market biomaterials and medical devices in the field of bone and tissue regeneration, wound healing, and osteoarthritis therapy.

Today, curasan has a presence in nearly 50 countries, gaining recognition around the world for manufacturing the highest quality products in both the dental and orthopedic markets. They have impressively shared its products with over two million patients, while continuing to uphold their commitment to providing optimal customer service and a full regenerative medicine product portfolio to encompass all of their clients’ needs. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader, curasan.

 

Bone Grafting & Product Overview

As one of their main focuses, curasan specializes mainly in biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic, and spinal applications. Numerous patents and a broad record of scientific publications demonstrate the clinical success of curasan´s highly innovative products, including their flagship biosynthetic product, CERASORB M®, which is part of the next generation of synthetic bone grafts.

It is designed and engineered to turnover bone in balance with the clinical needs of the patient, and has over 150 journal articles supporting its use. In addition to synthetic materials, curasan offers human allograft putties and both synthetic and collagen-based membranes.

While autograft is the gold standard for bone grafting, it can result in harvest site patient morbidity, and complications. For dental procedures where harvesting autograft isn’t feasible, an alternative is required that is easy to use and is effective. In many cases, you want to do more than just “repair” the problem—you want to regenerate the solution.

Treatment of bone defects continues to pose major challenges for dental clinicians. In order to re–establish bone stability, bone replacement and bone regeneration products are used on a regular basis. With easy ordering systems for products, the company offers a complete portfolio of osteobiologic materials, ranging from biosynthetics to tissue-based products. Depending on the indication, the user can choose between the partially resorbable bone replacement product Osbone® or fully resorbable bone replacement products from the CERASORB® product family.

In addition to these products, other bone graft substitutes include: Allosorb® and Osteoselect® DBM Putty.

Allosorb is the allograft that dental professionals choose to provide a natural osteoconductive structure to build healthy bone safely while OsteoSelect DBM Putty is a combination of human demineralized bone matrix (DBM) and a biocompatible and bioresorbable carrier (carboxymethylcellulose) that results in a putty with excellent handling characteristics. It can be easily molded into any shape and compressed into bony voids.

 

Commitment to Excellence

The company maintains its own high-tech facilities for research, development, and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan Inc., near Raleigh, NC, USA. They provides high quality competitively priced biomaterials for Oral Surgeons, Periodontists, General Dentists, Orthopedic Surgeons, and Neurosurgeons in the United States and Canada.

Their innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities. It is a public company and the shares of curasan AG are listed in the General Standard at the Frankfurt Stock Exchange.

Their main goal is to continue to provide its customers with high quality osteobiologics and membranes to satisfy the clinical needs of their patients. With an in depth understanding of the science and biology of bone grafting, they have put together a helpful and informative glossary to help their customers navigate through the process of introducing their products in their own businesses.

An interesting fact to consider comes from a recent series of reports on the European market for orthopedic biomaterials by iData Research, “synthetic products are becoming the preferred products over allografts, demineralized bone matrices (DBMs) and autografts, due to their affordability and easy accessibility. A wide range of synthetic products can offer flexibility and variety for different groups of patients.

 

Future Vision for curasan

As an organization curasan understands the importance of staying current as a dental provider, always keeping in touch with the market and researching trends for the future.

With a team of skilled and experienced professionals that incorporate human clinical data to show ultimate value for their customers, they design products and services only after performing extensive research.

They have made some important changes moving into the new year, to focus on and better serve their customers with relevant products and easier ordering to provide them with not only the best products, but to help make their businesses more efficient, and thus more effective.

In early Q2, curasan will offer a new line of bone grafts designed to offer a faster remodeling profile. The product, Osseolive® is currently in a post-market clinical evaluation with a two month re-entry bone assessment time point. Osseolive should deliver one of the fastest remodeling products on the market.

In the last 30 years of pioneering the industry of regenerative medicine, curasan has made a firm commitment to themselves and their customers to always stay informed of new technology and market trends.

Aligning with the industry’s best, curasan has already been exposed to cutting edge information this year at the IAOCI and the Chicago Mid-Winter meeting, which both occurred in February.

Along with their guarantee of staying informed as a global leader, they are proud of their achievements and look forward to sharing their continued success with their customers.

This commitment to knowledge and innovation, coupled with their promise of outstanding customer service, has been a successful formula that they only plan to build on as they continue to grow over the next 30 years and beyond.

Topics: Regenerative Medicine

Subscribe to Email Updates

Recent Posts